Creso Pharma Limited advised that it has significantly strengthened its Board and management team following the appointments of Mr. William Lay as Managing Director, leading cannabis and psychedelics entrepreneur, Mr. Bruce Linton as Non-Executive Director, and Mrs. Micheline McKay as Executive Director, effective immediately. Mr. William Lay is an experienced cannabis executive and previously served as Executive Vice President - Strategy, Origination & Operations at Creso Pharma. Mr. Lay began his career with leading Canadian full service financial investment bank, BMO Capital Markets through roles across Canada and London.

Shortly after his time with BMO Capital Markets, Mr. Lay joined Canopy Growth Corporation as an M&A Associate, before being promoted to Associate Director, M&A, in 2019. In this role, he assessed and effected multiple transactions locally and internationally, while concurrently progressing corporate strategy initiatives across the group. During his time at Canopy Growth, Mr. Lay built a strong working relationship with Mr. Linton, working on many high-profile initiatives together.

Over the last four years, Mr. Lay has managed and supported over CAD 5 billion in cannabis M&A transactions, including leading the acquisition in the history of the cannabis sector. In his new role as CEO and Managing Director of Creso Pharma, he will progress the Company's North American focused growth strategy, as well as Creso Pharma's proposed NASDAQ dual listing. Mr. Lay will also oversee the Company's global operations, including Creso Pharma's Swiss division and potential new market entries.

Creso Pharma plans to leverage Mr. Lay's extensive expertise to assess strategic, value accretive acquisitions in regions where it has an existing footprint, as well as for expansion purposes, with a particular focus on North America. Mr. Linton has been appointed as a Non-Executive Director in addition to his ongoing role as a strategic consultant for the Company. He is one of the leading cannabis executives, an accomplished entrepreneur and has extensive sector experience as a founder, CEO, Board member and advisor to a number of global cannabis and psychedelic focused companies.

As a Non-Executive Director, Mr. Linton will continue to provide strategic advice on the Company's operations and become more involved in progressing multiple, near-term corporate and operational initiatives with a focus on North America. Mr. Linton strengthens the Company's corporate governance mechanisms and adds independence to the Creso Pharma Board of directors. The Company plans to further utilise his deep cannabis and psychedelic industry experience to advance its growth trajectory.

Mrs. Micheline MacKay appointed as Executive Director: Mrs. MacKay has 22 years of experience in regulatory environments, including pharmaceuticals, medical devices, and government regulated industries. She has held leadership positions for many years in different areas with a strong focus on business improvements and product development from laboratory scale to commercial operations. Mrs. MacKay is currently the Corporate Manager of Creso Pharma's wholly owned Canadian subsidiary, Mernova Medicinal Inc. ("Mernova").

She has been in the position for nearly three years and is responsible for multiple functions including HR, quality assurance, and regulatory affairs. Mrs. MacKay is remunerated as an employee of Mernova and will not receive any additional remuneration for her role as a director of Creso. Mrs. MacKay will further strengthen the Company's Board through her extensive expertise across government and pharmaceutical industry regulation.

This will be pivotal as the Company continues to progress its growth trajectory as a leading drug and evolutionary therapies developer.